| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| BML Investment Partners, L.P. | 8.5% | +11.3% | $4.34M | $471K | 4.09M | +12.2% | Leonard Braden Michael | Jun 16, 2025 |
| BIOTECHNOLOGY VALUE FUND L P | 8.3% | $4.25M | 4.01M | BVF PARTNERS L P/IL | Dec 31, 2024 | |||
| GILEAD SCIENCES, INC. | 3.6% | $1.61M | 1.52M | GILEAD SCIENCES INC | Dec 31, 2024 | |||
| ORBIMED ADVISORS LLC | 6.92% | -57.6% | $820K | -$7.67M | 774K | -90.3% | ORBIMED ADVISORS LLC | Jul 25, 2025 |
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Change | Price | Investors |
|---|---|---|---|---|---|
| 2025 Q3 | 0 | $0 | -$42.6M | 0 | |
| 2025 Q2 | 31.8M | $42.6M | -$1.29M | $1.34 | 41 |
| 2025 Q1 | 32.7M | $41.9M | +$1.3M | $1.28 | 46 |
| 2024 Q4 | 31.7M | $52M | +$1.14M | $1.64 | 53 |
| 2024 Q3 | 28.4M | $49.1M | -$990K | $1.73 | 57 |
| 2024 Q2 | 29M | $47.9M | -$1.77M | $1.65 | 69 |
| 2024 Q1 | 30.1M | $42.7M | -$4.46M | $1.42 | 56 |
| 2023 Q4 | 32M | $63.1M | -$2.78M | $1.97 | 53 |
| 2023 Q3 | 32.7M | $142M | +$6.44M | $4.33 | 58 |
| 2023 Q2 | 31.2M | $205M | +$41.7M | $6.56 | 52 |
| 2023 Q1 | 25M | $86.2M | -$4.28M | $3.45 | 39 |
| 2022 Q4 | 26.3M | $69.9M | -$1.37M | $2.66 | 34 |
| 2022 Q3 | 26.2M | $93.2M | -$2.45M | $3.55 | 38 |
| 2022 Q2 | 26.8M | $119M | -$4.07M | $4.43 | 42 |
| 2022 Q1 | 27.5M | $168M | -$5.44M | $6.10 | 48 |
| 2021 Q4 | 27.4M | $344M | +$19.2M | $12.54 | 48 |
| 2021 Q3 | 19.8M | $249M | -$3.11M | $12.62 | 37 |
| 2021 Q2 | 21.1M | $293M | +$21.2M | $14.04 | 42 |
| 2021 Q1 | 19.3M | $539M | +$539M | $28.25 | 27 |